Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injury
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been recently discovered and validated as sensitive biomarkers that can predict stage 2 or 3 acute kidney injury (AKI) development in high-risk patients. We aimed to assess whether these biomarkers could predict adverse outcomes and renal recovery in established AKI patients. Methods: This was a single-center study prospectively enrolling 124 patients diagnosed with AKI. TIMP-2, IGFBP7, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1) levels were measured at the time of diagnosis and the predictive performance of short-term outcomes and renal recovery was assessed. Results: Patients were divided into 4 quartiles according to the initial urinary TIMP-2/IGFBP7 levels. Stage 3 AKI (odds ratio [OR], 17.86), classified by the Kidney Disease Improving Global Outcomes (KDIGO), as well as the third and fourth quartiles of TIMP-2/IGFBP7 (OR, 5.75 and 44.98, respectively), were found to be independent predictors of renal replacement therapy at the time of AKI diagnosis. In addition, KDIGO stage 3 AKI (OR, 2.468) or the third of fourth quartiles of urinary TIMP-2/IGFBP7 (OR, 1.896 and 3.622, respectively) were also found to be useful in predicting nonrecovery of renal function. In a separate analysis of patients with renal recovery at discharge, initial urinary TIMP-2/IGFBP7 or urinary IGFBP7 at discharge could also predict new-onset or progressive chronic kidney disease (CKD). Conclusions: In AKI patients, urine TIMP-2/IGFBP7 could serve as a biomarker for predicting adverse outcomes, renal recovery, or the development and progression of CKD.
Abstract
Background/Aims: Urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been recently discovered and validated as sensitive biomarkers that can predict stage 2 or 3 acute kidney injury (AKI) development in high-risk patients. We aimed to assess whether these biomarkers could predict adverse outcomes and renal recovery in established AKI patients. Methods: This was a single-center study prospectively enrolling 124 patients diagnosed with AKI. TIMP-2, IGFBP7, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1) levels were measured at the time of diagnosis and the predictive performance of short-term outcomes and renal recovery was assessed. Results: Patients were divided into 4 quartiles according to the initial urinary TIMP-2/IGFBP7 levels. Stage 3 AKI (odds ratio [OR], 17.86), classified by the Kidney Disease Improving Global Outcomes (KDIGO), as well as the third and fourth quartiles of TIMP-2/IGFBP7 (OR, 5.75 and 44.98, respectively), were found to be independent predictors of renal replacement therapy at the time of AKI diagnosis. In addition, KDIGO stage 3 AKI (OR, 2.468) or the third of fourth quartiles of urinary TIMP-2/IGFBP7 (OR, 1.896 and 3.622, respectively) were also found to be useful in predicting nonrecovery of renal function. In a separate analysis of patients with renal recovery at discharge, initial urinary TIMP-2/IGFBP7 or urinary IGFBP7 at discharge could also predict new-onset or progressive chronic kidney disease (CKD). Conclusions: In AKI patients, urine TIMP-2/IGFBP7 could serve as a biomarker for predicting adverse outcomes, renal recovery, or the development and progression of CKD.
참고문헌 (16)
- Lafrance JP, "Acute kidney injury associates with increased long-term mortality", J Am Soc Nephrol, 21, pp.345~352 (2010)
- Doyle JF, "Acute kidney injury : short-term and long-term effects", Crit Care, 20, pp.188~ (2016)
- Chawla LS, "Acute kidney injury and chronic kidney disease as interconnected syndromes", N Engl J Med, 371, pp.58~66 (2014)
- Leung KC, "Chronic kidney disease following acute kidney injury-risk and outcomes", Nat Rev Nephrol, 9, pp.77~85 (2013)
- Rifkin DE, "Does AKI truly lead to CKD", J Am Soc Nephrol, 23, pp.979~984 (2012)
- Kashani K, "Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury", Crit Care, 17, pp.R25~ (2013)
- Canaud G, "Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury", Nephrol Dial Transplant, 30, pp.575~583 (2015)
- Ronco C, "Cell cycle arrest biomarkers: new weapons for a new battle", Blood Purif, 38, pp.1~3 (2014)
- Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
- Wu VC, "Long-term risk of coronary events after AKI", J Am Soc Nephrol, 25, pp.595~605 (2014)
- Chawla LS, "Acute kidney injury and chronic kidney disease : an integrated clinical syndrome", Kidney Int, 82, pp.516~524 (2012)
- Koyner JL, "Tissue inhibitor metalloproteinase-2 (TIMP-2)⋅IGF-binding protein-7 (IGFBP7)levels are associated with adverse long-term outcomes in patients with AKI", J Am Soc Nephrol, 26, pp.1747~1754 (2015)
- Cruz DN, "Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population", Intensive Care Med, 36, pp.444~451 (2010)
- Aregger F, "Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury", Kidney Int, 85, pp.909~919 (2014)
- Sawhney S, "Longterm prognosis after acute kidney injury(AKI) : what is the role of baseline kidney function and recovery? A systematic review", BMJ Open, 5, pp.e006497~ (2015)
- Lim SY, "The impact of preexisting chronic kidney disease on the severity and recovery of acute kidney injury", Nephron, 139, pp.254~268 (2018)